Author Correction: Neoadjuvant durvalumab plus radiation versus durvalumab alone in stages I-III non-small cell lung cancer: survival outcomes and molecular correlates of a randomized phase II trial. uri icon

Overview

publication date

  • January 3, 2024

Identity

Digital Object Identifier (DOI)

  • 10.1038/s41467-023-44575-3

PubMed ID

  • 38172131

Additional Document Info

volume

  • 15

issue

  • 1